4.7 Article

Disease-associated KBTBD4 mutations in medulloblastoma elicit neomorphic ubiquitylation activity to promote CoREST degradation

Journal

CELL DEATH AND DIFFERENTIATION
Volume 29, Issue 10, Pages 1955-1969

Publisher

SPRINGERNATURE
DOI: 10.1038/s41418-022-00983-4

Keywords

-

Funding

  1. Medical Research Council (MRC) grant [MC_UU_00001/7]
  2. Cancer Research UK (CRUK) [DRCNPGMay21\100002]
  3. Brain Tumour Charity through an Expanding Theories award [GN-000559]
  4. Wellcome Trust [097813/Z/11/Z]
  5. Innovative Medicines Initiative 2 Joint Undertaking (JU) [875510]
  6. European Union's Horizon 2020 research and innovation programme
  7. EFPIA
  8. Ontario Institute for Cancer Research
  9. Royal Institution for the Advancement of Learning McGill University
  10. Kungliga Tekniska Hoegskolan
  11. Diamond Light Source Limited
  12. Wellcome strategic award [106169/ZZ14/Z]
  13. European Research Council Award microC [772970]
  14. China Scholarship Council -Nuffield Department of Medicine Scholarship
  15. CAPES [DPE 99999.013236/2013-00]
  16. Swiss National Science Foundation -Early Postdoc. Mobility program [P2GEP3_188295]
  17. Cancer Research UK
  18. [133/075]
  19. European Research Council (ERC) [772970] Funding Source: European Research Council (ERC)
  20. MRC [MC_UU_00001/7] Funding Source: UKRI
  21. Swiss National Science Foundation (SNF) [P2GEP3_188295] Funding Source: Swiss National Science Foundation (SNF)

Ask authors/readers for more resources

Medulloblastoma is a common malignant brain tumor in children, and it has been found to have different subtypes based on genomic studies. WNT and SHH signaling pathway alterations are known to be the main causes for their subtypes, but the causes for non-WNT/non-SHH tumors are still largely unknown. Recent studies have identified KBTBD4 gene mutations as important drivers in group 3 and group 4 medulloblastomas. These mutations promote significant changes in chromatin accessibility and transcriptional programs, leading to increased stemness of cancer cells.
Medulloblastoma is the most common malignant brain tumour in children. Genomic studies have identified distinct disease subgroups: wnt/wingless (WNT), sonic hedgehog (SHH), and non-WNT/non-SHH, comprising group 3 and group 4. Alterations in WNT and SHH signalling form the pathogenetic basis for their subgroups, whereas those for non-WNT/non-SHH tumours remain largely elusive. Recent analyses have revealed recurrent in-frame insertions in the E3 ubiquitin ligase adaptor Kelch Repeat and BTB Domain Containing 4 (KBTBD4) in cases of group 3/4 medulloblastoma. Critically, group 3/4 tumours with KBTBD4 mutations typically lack other gene-specific alterations, such as MYC amplification, indicating KBTBD4 insertion mutations as the primary genetic driver. Delineating the role of KBTBD4 mutations thus offers significant opportunities to understand tumour pathogenesis and to exploit the underpinning mechanisms therapeutically. Here, we show a novel mechanism in cancer pathogenesis whereby indel mutations in KBTBD4 drive its recognition of neo-substrates for degradation. We observe that KBTBD4 mutants promote the recruitment and ubiquitylation of the REST Corepressor (CoREST), which forms a complex to modulate chromatin accessibility and transcriptional programmes. The degradation of CoREST promoted by KBTBD4 mutation diverts epigenetic programmes inducing significant alterations in transcription to promote increased stemness of cancer cells. Transcriptional analysis of >200 human group 3 and 4 medulloblastomas by RNA-seq, highlights the presence of CoREST and stem-like signatures in tumours with KBTBD4 mutations, which extend to a further sub-set of non-mutant tumours, suggesting CoREST alterations as a novel pathogenetic mechanism of wide relevance in groups 3 and 4. Our findings uncover KBTBD4 mutation as a novel driver of epigenetic reprogramming in non-WNT/non-SHH medulloblastoma, establish a novel mode of tumorigenesis through gain-of-function mutations in ubiquitin ligases (neo-substrate recruitment) and identify both mutant KBTBD4 and CoREST complexes as new druggable targets for improved tumour-specific therapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available